A comprehensive review, published in Frontiers in Cardiovascular Medicine, has highlighted the complex and often contradictory roles of interleukin (IL) cytokines in vascular calcification (VC). It is a major driver of cardiovascular disease in conditions such as atherosclerosis, chronic kidney disease, and diabetes.
VC, initially considered as a passive degenerative process, is now recognized as an active cellular phenomenon involving vascular smooth muscle cells (VSMCs). This review highlights how chronic inflammation, mediated by the IL family, is central to this transformation. 

Pro-inflammatory cytokines such as IL-1β, IL-6, and IL-17 activate pathways including NF-κB, JAK/STAT, and Wnt/β-catenin, which induce osteogenic markers like Runx2 and BMP-2, accelerating calcium deposition in arteries. Some cytokines with anti-inflammatory properties, including IL-10 and IL-37, counteract calcification by suppressing inflammatory signaling, enhancing autophagy, and preserving calcium-phosphate balance. Some ILs, such as IL-4, IL-13, and IL-18, display dual roles depending on the microenvironment properties, which further complicates therapeutic targeting.

Certain cutting-edge strategies to modulate these pathways are also explained in this review. Novel nanodelivery systems and multi-target interventions such as TYK2 inhibitors and IL-6 trans-signaling blockers show potential for targeted treatments. However, clinical practice is hindered by safety concerns, particularly infection risks linked to long-term immunosuppression.

These findings highlight the need for precision approaches that consider spatiotemporal signaling heterogeneity and individual patient immune status. Future therapies may combine biomarker-driven patient selection with advanced drug delivery platforms to balance efficacy with safety. The new information positions the IL family not only as key mediators of vascular pathology but also as promising therapeutic targets for halting or reversing calcification in chronic disease.